Predictive Oncology Inc.’s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labs
June 22 2021 - 08:30AM
Predictive Oncology (NASDAQ: POAI), an AI-driven
oncology and drug discovery company, announced today that two of
their wholly owned subsidiaries, Soluble Biotech Inc. and
TumorGenesis Inc. are both expanding their unique services by
completing the fabrication and qualification of GMP facilities.
Soluble Biotech Inc., located in Birmingham,
Alabama, uses a proprietary technology to rapidly develop
formulations for protein and peptide therapeutics (i.e., vaccines,
antibodies, virus-like particles, etc.). The GMP facility will
allow the company to provide their customers with formulations that
can be directly used in clinical trials. This new capability is
expected to significantly expand Soluble Biotech’s growing
potential customer base and it is hoped to lead to long-term
partnerships with pharmaceutical and biotech companies. Soluble
Biotech also sells chromatography kits that contain their
proprietary, highly efficient endotoxin removal media. Soluble’s
new GMP facility will be used to produce this media for
pharmaceutical and biotechnology companies as one of their final
protein purification steps prior to entering animal or human
trials.
“The addition of a GMP facility is expected to
significantly increase our potential customer base and lead to
multiple long-term collaborations,” said Dr. Larry DeLucas, Vice
President of Operations at Predictive Oncology.
TumorGenesis Inc., located in Salem,
Massachusetts, is also implementing GMP operations for its
production of cancer cell media and other products used in the
capture, culture, identification, and screening of ovarian and
breast cancer cells. The media, used to “fool” cancer cells into
behaving as if they were still in the body, can also be used along
with new technologies in cancer cell editing to produce proteins
and other biological products that can be used to diagnose, treat,
or modify cancer cells.
“By having the ability to scale into GMP
production of media, we will be able to meet the needs of
researchers who are exploring ways to use the cancer cell’s own
mechanisms to produce a target, expressed protein or biological
target,” said Richard Gabriel, Senior Vice President of Research
and Development at Predictive Oncology.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates
through three segments (Skyline, Helomics and Soluble Biotech),
which contain four subsidiaries: Helomics, TumorGenesis, Skyline
Medical and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement, and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins, and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain
forward-looking statements. These forward-looking statements
reflect our current expectations and projections about future
events and are subject to substantial risks, uncertainties and
assumptions about our operations and the investments we make. All
statements, other than statements of historical facts, included in
this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify forward-
looking statements, although not all forward-looking statements
contain these identifying words. Our actual future performance may
materially differ from that contemplated by the forward-looking
statements because of a variety of factors including, among other
things, factors discussed under the heading “Risk Factors” in our
filings with the SEC. Except as expressly required by law, the
Company disclaims any intent or obligation to update these
forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2023 to Mar 2024